Research News

BrightFocus-funded research offers the potential to restore vision loss due to glaucoma using cell replacement therapy.

A team of BrightFocus-funded scientists has proposed a new explanation and possible new target for treatment in glaucoma that’s unrelated to the common culprit of eye pressure.

Jason Meyer, PhD, is a BrightFocus Foundation success story and a pioneer in the effort to regenerate eye tissue that is damaged by glaucoma. 

Recently, when their groundbreaking genetics discovery was featured on the cover of Nature, the research team thanked BrightFocus for critical early funding that supported their accomplishments.

An interdisciplinary team of Harvard scientists has successfully reprogrammed cells in mice to reverse vision loss from glaucoma, as well as normal (not disease-related) vision loss associated with aging in mouse models.

Working to save sight, BrightFocus’ National Glaucoma Research program is supporting Kathryn Burdon, PhD, of Australia’s University of Tazmania and Girum Gessesse, MD, of Ethiopia’s St. Paul’s Hospital Millennium Medical College to expand our scientific understanding of glaucoma in Africa.

The research and discoveries of clinician-scientist Joel S. Schuman, MD, are having a big impact on vision diseases, including glaucoma. Early support from BrightFocus had a big impact on his career.

Two new pressure-lowering glaucoma medications have been approved by the FDA and are becoming available in the United States. Each is unique, and one is the first in a new class of drugs.

BrightFocus Foundation has joined a new partnership to support innovative science to regenerate damaged visual pathways in glaucoma.

Read our interview with Dr. Elliott where he talks about his original hypothesis and his exciting new research directions.